This study investigates the effects of combining celecoxib with gemcitabine in treating pancreatic cancer.
The study evaluates the potential benefits of adding celecoxib to the standard gemcitabine treatment. It focuses on assessing the safety and effectiveness of this combination therapy.
- Who can participate: Participants must be 18 years or older and have undergone surgery for R0 resection. They should not have used gemcitabine for other cancers and must meet specific health criteria.
- Study details: Participants will receive either gemcitabine alone or in combination with celecoxib. The effects on survival and side effects will be monitored.